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Abstract
Background: The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, is currently
being introduced throughout the African meningitis belt. In repeated multicentre cross-sectional studies in Burkina
Faso we demonstrated a significant effect of vaccination on NmA carriage for one year following mass vaccination
in 2010. A new multicentre carriage study was performed in October-November 2012, two years after MenAfriVac
mass vaccination.
Methods: Oropharyngeal samples were collected and analysed for presence of N. meningitidis (Nm) from a
representative selection of 1-29-year-olds in three districts in Burkina Faso using the same procedures as in previous
years. Characterization of Nm isolates included serogrouping, multilocus sequence typing, and porA and fetA
sequencing. A small sample of invasive isolates collected during the epidemic season of 2012 through the national
surveillance system were also analysed.
Results: From a total of 4964 oropharyngeal samples, overall meningococcal carriage prevalence was 7.86%. NmA
prevalence was 0.02% (1 carrier), significantly lower (OR, 0.05, P = 0.005, 95% CI, 0.006-0.403) than pre-vaccination
prevalence (0.39%). The single NmA isolate was sequence type (ST)-7, P1.20,9;F3-1, a clone last identified in Burkina
Faso in 2003. Nm serogroup W (NmW) dominated with a carriage prevalence of 6.85%, representing 87.2% of the
isolates. Of 161 NmW isolates characterized by molecular techniques, 94% belonged to the ST-11 clonal complex
and 6% to the ST-175 complex. Nm serogroup X (NmX) was carried by 0.60% of the participants and ST-181
accounted for 97% of the NmX isolates. Carriage prevalence of serogroup Y and non-groupable Nm was 0.20% and
0.18%, respectively. Among the 20 isolates recovered from meningitis cases, NmW dominated (70%), followed by
NmX (25%). ST-2859, the only ST with a serogroup A capsule found in Burkina Faso since 2004, was not found with
another capsule, neither among carriage nor invasive isolates.
Conclusions: The significant reduction of NmA carriage still persisted two years following MenAfriVac vaccination,
and no cases of NmA meningitis were recorded. High carriage prevalence of NmW ST-11 was consistent with the
many cases of NmW meningitis in the epidemic season of 2012 and the high proportion of NmW ST-11 among the
characterized invasive isolates.
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Background
Bacterial meningitis in sub-Saharan Africa has mainly
been caused by N. meningitidis (Nm) with localized out-
breaks or large epidemics occurring every year in the dry
season [1-4]. The number of cases usually increases in
January and drops in April-May with the first rainfall.
Nm is normally colonising the upper respiratory tract
in humans without causing disease [3,5,6]. The bacteria
circulate in the human population by transmitting from
person to person through droplets and close contact.
However, occasionally Nm may infect the blood and cause
meningitis and/or septicaemia, with a possible fatal out-
come occurring within hours.
Nm is classified into serogroups according to the struc-
ture of its polysaccharide capsule. In the meningitis belt,
epidemics have essentially been caused by Nm of sero-
groups A (NmA), but serogroups W (NmW) and X
(NmX) have also caused large outbreaks [7-9].
As the capsule is immunogenic and probably the most
important virulence factor, capsular polysaccharide of
serogroups A, C, W and Y has been used as vaccine anti-
gens. Until very recently, A/C and A/C/W polysaccharide
vaccines have been the only vaccines available for use in
sub-Saharan Africa. Due to the relative short protection
provided by polysaccharide vaccines and their inability to
elicit a good antibody response in children below 2 years
of age, these vaccines have been used mainly to stop
ongoing outbreaks [10]. Following the success of Hae-
mophilus influenzae type b and pneumococcal conjugate
vaccines, Nm vaccines coupling a carrier protein to the
main disease-causing polysaccharide serogroups were de-
veloped. In addition to eliciting strong and long lasting
immune response in children below 2 years [5,11], conju-
gate vaccines have also been shown to confer herd protec-
tion by reducing the carriage prevalence, thus interrupting
transmission [12-16].
A monovalent serogroup A tetanus toxoid-conjugated
vaccine, MenAfriVac, has been developed with the goal
of eliminating the devastating NmA epidemics in Africa
[17-19]. The vaccine was shown to be safe and immuno-
genic [20] and its low price made it appropriate for routine
vaccination and mass vaccination campaigns in Africa.
MenAfriVac was prequalified by the World Health
Organization (WHO) in June 2010 to be given as a sin-
gle dose in the age group 1–29 years.
Being a conjugate vaccine, it was hoped that MenAfriVac
will have an effect on NmA carriage, similarly to what
has been found in the UK following vaccination campaign
with a monovalent serogroup C conjugate on NmC car-
riage [14,15]. Given the fact that not all age-groups were
eligible to receive the vaccine, impact of vaccination on
meningococcal carriage would be beneficial for the whole
population by reducing transmission. To demonstrate
the impact of this new vaccine in an African setting,
meningococcal carriage studies were planned ahead of
MenAfriVac implementation in the meningitis belt.
Burkina Faso was the first country to vaccinate the
whole 1-29-year-old population in 2010 [21]. Mali and
Niger introduced the vaccine in 2010–2011 and other
countries of the meningitis belt rapidly followed; over
150 million people had received the vaccine by the end
of 2013. The impact of MenAfriVac on NmA disease
and carriage, and the evidence of herd immunity, were
first demonstrated in Burkina Faso. The risk for menin-
gitis significantly decreased in all age groups, not only
in the 1–29 year-old vaccinated population, and based
on laboratory-confirmed cases, the risk for NmA men-
ingitis was reduced by 99.8% [22]. Up to 13 months after
vaccination, NmA carriage remained undetected among
both vaccinated and unvaccinated populations [23] and
there was no evidence of capsule replacement of the
ST-2859 clone previously responsible for NmA disease
and carriage in Burkina Faso [24]. Similar results were
recently reported from Chad that experienced an epi-
demic in 2010; outbreaks of NmA meningitis occurred
only in non-vaccinated districts and NmA carriage was
significantly lower 4–6 months after vaccination [25].
As the vaccine is not yet introduced in childhood vac-
cination programs, the impact of this public health
intervention relies in large part on the herd protection
afforded by the vaccine. It is thus important to docu-
ment how long this protection will last through contin-
ued laboratory-based surveillance and follow-up studies
on carriage.
To study the long term impact of MenAfriVac vaccin-
ation on carriage, an existing multicentre carriage study
in Burkina Faso was extended and conducted in October-
November 2012 using the same protocol as in previous
years. Results from this carriage sampling together with
molecular characterization of invasive isolates collected
through surveillance are presented here.
Methods
Ethics
The carriage study obtained ethical clearance from the
Norwegian Regional Committee for Medical Research
Ethics, Southern Norway, the Ethical Committee for
Health Research in Burkina Faso and the Institutional
Review Board at the Centers for Disease Control and
Prevention (CDC), Atlanta, USA. Informed written con-
sent was obtained from the participants or from their
parent or guardian if the participant was < 18 years.
The invasive isolates were collected within the national
surveillance system and did not require ethical approval.
Carriage study design and oversight
The study was a continuation of a previously described
multicentre repeated cross-sectional survey in three health
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districts in Burkina Faso [19]. Data presented here were
collected during the tenth cross-sectional survey, desig-
nated Sampling 10 (S10). During four weeks, between the
15th of October and 11th of November 2012, we con-
ducted a study of oropharyngeal carriage among 1-29-
year-olds, in the urban district of Bogodogo and the two
rural districts of Dandé and Kaya. MenAfriVac was first
introduced in Kaya in mid-September 2010, while the rest
of the country, including Bogodogo and Dandé introduced
the vaccine in early December 2010. We consider this
sampling campaign to be two years after vaccination for
all three districts (range 23–25 months).
Using a multistage cluster design we randomly selected
households in each district in which all healthy 1-29-year-
olds were invited to participate, whether or not they had
previously been vaccinated with MenAfriVac. Informed
consent was obtained from each participant or guardian
if the subject was < 18 years. Demographic data and
MenAfriVac vaccination status for each participant was
collected on personal digital assistants (PDAs).
Collection of carriage isolates
The procedures for sampling and laboratory analysis
have been described elsewhere [26,27]. Oropharyngeal
samples were collected in the field by swabbing the pos-
terior pharyngeal wall and one tonsil. The samples from
Bogodogo were analyzed at the Centre Hospitalier Univer-
sitaire Pédiatrique Charles de Gaulle in Ouagadougou, the
samples from Dandé at the Centre Hospitalier Universi-
taire Souro Sanou in Bobo-Dioulasso and the samples
from Kaya at the Centre Hospitalier Régional in Kaya.
The laboratory analyses included examination of col-
ony morphology, oxidase test, Gram staining, enzymatic
tests for detection of β-galactosidase (ONPG) and γ-
glutamyltransferase (GGT) and serogrouping by slide
agglutination, as previously described [26]. Oxidase-
positive, Gram-negative diplococcic, ONPG-negative
and GGT-positive isolates were considered as presump-
tive Nm and shipped to the Norwegian Institute of
Public Health (NIPH), Oslo, Norway, for confirmatory
analyses and molecular characterization.
Laboratory quality control
A laboratory quality control (QC) system for assessing
the quality of the carriage study in Burkina Faso was
followed [27]. It included control of reagents, media and
incubation conditions (internal QC), and the re-analysis
of a subset of Nm-negative samples taken from two cri-
tical analytical steps: the identification of Nm colonies
growing on the selective agar plate based on colony
morphology, and the enzymatic tests (external QC). Ex-
ternal QC was performed by NIPH and enabled the as-
sessment of sensitivity and specificity of laboratory
analysis using standard formulas, as described [27].
Data management and statistical analyses
Demographic data from participants in the carriage study
and laboratory data from Burkina Faso and Norway were
merged into a combined database in Access (Microsoft
Corporation, Redmond, WA). Samples without complete
traceability, due to missing or duplicated links between
the laboratory result and the demographic data of the par-
ticipant, were excluded from the analysis.
During recruitment of participants we asked whether or
not they had been vaccinated with MenAfriVac. For the
estimation of vaccine coverage, those responding “no” or
“don’t know” were considered as not vaccinated in order
to present the most conservative coverage estimate.
Data analysis was performed in STATA 12 [28] and
Excel 2010 (Microsoft Corporation, Redmond, WA). Bi-
variate analysis was done using odds ratio (OR) and 95%
confidence interval (CI) calculations corrected for the
cluster sampling design.
Collection of invasive isolates
Among 843 culture-positive cerebrospinal fluid (CSF)
isolates collected during the 2012 epidemic season, 20
that had been processed at the Centre Hospitalier Uni-
versitaire Pédiatrique Charles de Gaulle were sent in
Trans-isolate medium [29] to the WHO Collaborating
Centre for Reference and Research on Meningococci at
NIPH. Fifteen were culture-positive on arrival at NIPH.
Strain characterization
DNA from each Nm strain was extracted by suspending
1 loop of bacteria in 200 μl Tris-EDTA (TE) buffer,
pH 8.0, heating at 95°C for 10 minutes, centrifugation at
16,000 × g for 5 min and storing the supernatant at −20°C
until use.
For the carriage isolates and culture-positive invasive
isolates, molecular characterization consisted of the de-
termination of the sequence type (ST) by multilocus se-
quence typing (MLST) [30], and the variant of outer
membrane protein PorA and FetA by DNA sequencing
of the porA and fetA genes [31,32], using the primers rec-
ommended on the MLST website (http://pubmlst.org/
neisseria). For isolates found to be non-serogroupable
(NG) by slide agglutination, the serogroup was deter-
mined by capsule-gene PCR [33].
Invasive isolates were further characterized by antibiotic
susceptibility to ciprofloxacin, ceftriaxone, rifampicin,
penicillin G, sulphonamides, tetracycline and chloram-
phenicol. Each isolate was classified according to the
European Committee on Antibiotic Susceptibility Testing
breakpoints (www.eucast.org) based on minimal inhibitory
concentration (MIC) to each antibiotic as determined by
Etest (Biomérieux, France).
For culture-negative invasive isolates, the charac-
terization was restricted to capsule-gene PCR and the
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determination of PorA variant by DNA sequencing of
the porA gene using a nested porA-PCR [34].
Results
The carriage study
Study population and samples
The carriage study resulted in the collection and analysis
of 4982 samples. Of these, 18 samples were excluded
due to missing or duplicated links to the demographic
data of the person swabbed. Thus, the total sample sizes
used for the analysis were 4964, 1632 from Bogodogo,
1655 from Dandé and 1677 from Kaya. None of the ex-
cluded samples were Nm-positive.
The proportion of males was 43.4%, and 53.6% of all
the participants were between 1 and 9 years of age. Based
on the questionnaire, MenAfriVac vaccination coverage
was 78.8% across all age groups, with 54.5% confirmed by
presentation of the vaccination card. Vaccination coverage
varied by age. Although none of the children below 2 years
of age were old enough to be vaccinated in December
2010, 6.3% and 16.2% of the 1 and 2 years old, respec-
tively, were reported to have received the vaccine. Cover-
age in the 3-year-olds was 61.1% while coverage in the
4-29-year-olds ranged from 78.5-96.6%.
Meningococcal carriage by serogroup and ST
Of the 4964 participants included in the analysis, 390
(7.86%) were carriers of Nm. Carriage prevalence varied
by district: prevalence was highest in Dandé (17.70%),
followed by Kaya (3.34%) and Bogodogo (2.51%) (Table 1).
One single NmA carrier was identified among the 4964
participants (0.02%). Compared to a pre-vaccination car-
riage prevalence of 0.39% [26], the measured prevalence
was significantly lower (OR, 0.05, P = 0.005, 95% CI,
0.006-0.403). This strain was assigned to the ST-7 of the
ST-5 clonal complex, with PorA;FetA variants P1.20,9;
F3-1. The isolate came from a 13 year-old vaccinated
boy living in the Bogodogo district. His vaccination sta-
tus was confirmed by vaccination card. The family had
received visitors from Ivory Coast shortly before the
sample was taken. Within the boy’s household, three other
persons aged 9, 18 and 21 years, were also included in the
study: none of them were carriers.
NmW dominated in all three districts and accounted
for 97%, 66% and 52% of the Nm isolates in the districts
of Dandé, Bogodogo and Kaya, respectively. All the NmW
carriage isolates from Bogodogo and Kaya were subjected
to molecular characterization while of the 284 NmW iso-
lates from Dandé, a subset of 105 isolates was character-
ized using molecular methods. The subset included every
fourth isolate determined as NmW by slide agglutination
and all NG by slide agglutination that were serogroup W
by PCR. The majority of the characterized NmW iso-
lates from all three districts were assigned to ST-11 of
the ST-11 clonal complex. In Dandé as many as 98.1%
of the NmW isolates were ST-11, while one isolate
was ST-10171, a single locus variant of ST-11, and one
isolate was ST-2881 of the ST-175 complex (Table 2).
By extrapolating the characteristics of the subset of iso-
lates from Dandé, we estimated that carriage prevalence
of NmW ST-11 in Dandé was 16.7%. Prevalence of
NmW ST-11 in Bogodogo and Kaya was 1.2% and 1.1%,
respectively.
NmX was the second most prevalent serogroup, found
in 0.6% of the participants (Table 1). In Dandé this sero-
group represented only 1.7% of the carriage isolates
while in Bogodogo and Kaya the proportion was at
12.2% and 35.7%, respectively. All the 30 NmX isolates
were assigned to the ST-181 complex, 29 (96.7%) to
ST-181 and 1 (0.3%) to ST-10169 (Table 2).
Overall carriage of NmY and NmNG was low at 0.20%
and 0.18%, respectively (Table 1). Serogroup Y was highest
in Kaya (0.36%), while NmNG was highest in Bogodogo
(0.37%).
Comparisons of carriage prevalence of meningococci
assigned to the ST-23, ST-181 and ST-11 clonal com-
plexes with data from the three previous years are pre-
sented in Figure 1. Overall carriage of ST-11 associated
isolates increased from 0.22% in 2011 to 6.61% in 2012
and the increase was highest in Dandé; from 0.39% to
Table 1 Meningococcal carriage in Burkina Faso two years after mass vaccination with MenAfriVac
District
Bogodogo (N = 1632) Dandé (N = 1655) Kaya (N = 1677) Total (N = 4964)
Serogroup
A 1 (0.06%) 0 0 1 (0.02%)
W 27 (1.65%) 284a (17.16%) 29 (1.73%) 340 (6.85%)
X 5 (0.31%) 5 (0.30%) 20 (1.19%) 30 (0.60%)
Y 2 (0.12%) 2 (0.12%) 6 (0.36%) 10 (0.20%)
NGb 6 (0.37%) 2 (0.12%) 1 (0.06%) 9 (0.18%)
Total 41 (2.51%) 293 (17.70%) 56 (3.34%) 390 (7.86%)
aOf these, 105 isolates were randomly selected for molecular characterization.
bNG, Nongroupable Neisseria meningitidis.
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16.98%. In contrast, carriage prevalence of meningococci
assigned to ST-23 and ST-181 decreased from 2011 to
2012 (Figure 1).
Meningococcal carriage by age and sex
Carriage prevalence was higher among male participants
(8.72%) than females (7.19%) but the difference was not
statistically significant when correcting for the cluster
sampling design (P = 0.104). Prevalence varied with age
with a peak at 11.20% in the 5-9-year-olds (Figure 2).
We observed different age-related trends in carriage pre-
valence for males and females (Figure 2). For female par-
ticipants, carriage was highest in the age group 5–9 years
(12.09%) while for males the maximum carriage preva-
lence was found in 10-14-year-olds (12.09%) (Figure 2).
The dominant NmW was the only serogroup showing a
marked difference between age groups in terms of preva-
lence, because the other serogroups were represented by
relatively few isolates (Figure 3).
Carriage of N. lactamica
Isolates with Gram-negative diplococcic morphology,
oxidase-positive and ONPG-positive reactions, belonging
to the closely related species N. lactamica, were identi-
fied in 18.71% of the samples. Carriage was age-dependent
with highest prevalence in 1–3 years old children (average,
36.5%, range 35.0-37.8%) and declining from the age of
3 years until the age of 19 years (Figure 2). Among par-
ticipants ≥ 20 years, carriage of N. lactamica remained
within a range of 7.2-8.5%, carriage among women was
higher (range, 7.9%-9.0%) compared to males (range
1.1%-5.1%).
Table 2 Molecular characteristics of meningococcal carriage isolates in the districts of Bogodogo (B), Dandé (D) and
Kaya (K) in Burkina Faso two years after MenAfriVac vaccination
Serogroup ST-complex ST
no
PorA FetA No. of
isolates
By districta
B D K
A 5 7 P1.20,9 F3-1 1 1 0 0
W 11 11 P1.5,2 F1-1 126 19 86 21
11 11 P1.5,2 F1-31 1 0 0 1
11 11 P1.5,2 F3-56 1 0 0 1
11 11 P1.5,2 F6-3 20 1 17 2
11 9927 P1.5,2 F1-1 1 1 0 0
11 10170 P1.5,2 F1-1 1 1 0 0
11 10171 P1.5,2 F1-1 1 0 1 0
175 2881 P1.5-1,2-36 F5-1 7 3 1 3
175 9357 P1.5-1,2-36 F5-1 3 2 0 1
X 181 181 P1.5-1,10-1 F1-31 25 4 5 16
181 181 P1.5-1,10-1 F1-147 1 0 0 1
181 181 P1.5-1,10-1 F5-69 3 0 0 3
181 10169 P1.5-1,10-1 F1-31 1 1 0 0
Y 167 767 P1.5-1,10-8 F1-3 1 0 0 1
175 2881 P1. 21–14,28-3 F5-1 3 0 0 3
23 1622 P1.5-1,2-2 F5-8 1 0 1 0
23 4375 P1.5-1,2-2 F5-8 2 0 1 1
UAc 192 P1.18-11,42-1 Neg.d 3 2 0 1
NGb 175 2881 P1.5-1,2-78 F5-1 2 0 2 0
175 9357 P1.5-1,2-77 F5-1 1 1 0 0
198 198 P1.18-24,25 F5-5 1 1 0 0
UAc 192 P1.18-11,42-1 Neg.d 2 2 0 0
UAc 4899 P1.21-14,28-3 F5-66 2 1 0 1
UAc 8248 P1.21-14,28-3 F5-66 1 1 0 0
aDistricts of Bogodogo (B), Dandé (D) and Kaya (K).
bNG, Nongroupable Neisseria meningitidis.
cUA, Unassigned to any clonal complex.
dNegative.
ST, Sequence Type; CC, Clonal complex.
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Figure 1 Evolution of carriage prevalence for the dominant clonal complexes in Burkina Faso, 2009–2012. The figure shows the
carriage prevalence (%) of ST-23, ST-181 and ST-11 clonal complexes on a logarithmic scale in each study sites in Burkina Faso at ten sampling
timepoints, S1-S10.
Figure 2 Carriage prevalence of N. meningitidis by age and gender and prevalence of N. lactamica by age in Burkina Faso in 2012.
The figure shows carriage prevalence (%) of N. meningitidis by age and gender (left secondary axis) together with carriage prevalence (%) of
N. lactamica by age (right secondary axis).
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Laboratory QC
QC samples (n = 270) that were determined as not har-
bouring Nm in Burkina Faso were re-analysed at NIPH;
150 were from the analytical step where colonies are
picked from the primary agar plate for further analysis,
based on colony morphology and 120 from the enzy-
matic ONPG and GGT tests. In total, 3 samples were
identified as Nm and included in the data analysis: two
isolates were from Bogodogo (NmW ST-11 and NmW
ST-2881) and one isolate was from Dandé (NmW ST-11).
When extrapolating the proportion of missed Nm in
the two steps included in the QC to the total number
of samples analysed, we estimated that 30 Nm may have
been missed. Thus, the overall carriage rate of 7.86% was
probably a slight underestimation and the prevalence
should likely be corrected to 8.40%. Of the 404 presump-
tive Nm-positive samples sent to NIPH for confirmation
and further characterisation, 387 were true positive
(95.8%) while 17 were not Nm. Based on these numbers
we calculated the sensitivity and specificity of meningo-
coccal isolation and identification in Burkina Faso to be
92.8% and 99.6%, respectively.
Clinical isolates
Sample collection
Of the 20 isolates sent to NIPH on trans-isolate medium,
15 were culture-positive upon arrival and characterized by
serogrouping, MLST, porA/fetA sequencing (Table 3) and
antibiotic susceptibility. The remaining 5 samples did not
grow and were analysed by capsule gene PCR and porA
sequencing.
Characteristics of invasive isolates
The 20 CSF isolates included 14 NmW, 5 NmX and 1
NmY. The NmW isolates all had PorA variant P1.5,2
and the culture-positive samples all belonged to the
ST-11 clonal complex and were assigned to either ST-11,
ST-2724 or ST-9766 (Table 3). The NmX isolates had
either PorA variant P1.5-1,10-1 (4 of 5 isolates) or
P1.7,16-46 (1 isolate). The 3 NmX isolates with a MLST
result were assigned to ST-181 of the ST-181 clonal
complex. The NmY isolate was assigned to ST-4375 of
the ST-23 clonal complex. None of the clinical isolates
were serogroup A or assigned to the ST-5 clonal complex,
Figure 3 Meningococcal carriage prevalence in Burkina Faso in 2012, by age and serogroup. The figure shows meningococcal carriage
prevalence (%) by age for all meningococci (Nm) and for serogroups W, X, Y and nongroupable (NG) meningococci.
Table 3 Molecular characteristics of 20 meningococcal isolates from cerebrospinal fluid samples collected in Burkina
Faso during the epidemic season of 2012
Serogroup Culture ST-complex ST no PorA FetA No. of isolates
W Pos. 11 11 P1.5,2 F1-1 9
Pos. 11 2724 P1.5,2 F1-1 1
Pos. 11 9766 P1.5,2 F1-1 1
Neg. ND ND P1.5,2 ND 3
X Pos. 181 181 P1.5-1,10-1 F1-31 3
Neg. ND ND P1.5-1,10-1 ND 1
Neg. ND ND P1.7,16-46 ND 1
Y Pos. 23 4375 P1.5-1,2-2 F5-8 1
ND, Not determined.
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the only clonal complex responsible for NmA disease in
sub-Saharan Africa in the past decades [8,24,35].
The 15 culture-positive isolates were susceptible to
ciprofloxacin (MIC range, <0.002 – 0.008), ceftriaxone
(MIC, < 0.002), rifampicin (MIC range, 0.008 – 0.25),
penicillin G (MIC range, 0.032 – 0.125), tetracycline
(MIC range, 0.125 – 0.25) and chloramphenicol (MIC
range, 0.5 – 1.0). All the NmW strains were resistant to
sulfamethoxazole (MIC > 1024) while the serogroups X
and Y isolates were susceptible (MIC range, 0.5 – 2.0).
Discussion
This study describes meningococcal carriage in Burkina
Faso in October-November 2012, two years after the in-
troduction of MenAfriVac. Molecular characteristics of
the carriage isolates were compared to those of invasive
isolates collected during the 2012 epidemic season. The
significant reduction of NmA carriage after MenAfriVac
vaccination still persisted. Serogroup W dominated both
among carriage and patient isolates.
Although the small collection of invasive isolates that
we analyzed was not a random selection, it reflected to
some extent the characteristics of meningococcal disease
isolates in Burkina Faso in 2012. Our collection was com-
posed of 75% NmW and 20% NmX, which is comparable
to the WHO surveillance data from the 2012 epidemic
season showing that among the laboratory confirmed
cases caused by Nm, 83.5% were NmW and 16.4% were
NmX [36]. Analysis of a larger sample of invasive isolates
collected from Burkina Faso in 2012 newly confirmed that
all the NmW isolates belonged to the ST-11 complex [37].
A single NmY case was identified and this isolate was in-
cluded in our strain collection. The surveillance system in
Burkina Faso was strong in this period: of 6957 cases of
suspect meningitis cases reported in 2012, 3292 CSF sam-
ples were collected, of which 1105 were reported with a
laboratory result [36]. No cases of NmA meningitis were
reported during the 2012, 2013 and 2014 epidemic sea-
sons, before and after the carriage study [36].
This carriage study was the tenth sampling campaign
performed in the same districts of Burkina Faso since
2009 [23,24,26,27]. Efforts were made to keep all condi-
tions as similar as possible to those in previous sam-
plings. We used the same protocol, reagents, equipment
and QC system. The teams were composed of essentially
the same persons and retraining was conducted prior
to start. The sensitivity and specificity of laboratory
analysis in Burkina Faso, as extracted from the QC sys-
tem, were comparable to previous campaigns [23,26,27]
and show that variation of carriage prevalence was not
due to variation in the quality of the analysis. Further-
more, the carriage prevalence of N. lactamica was within
the range obtained from all the previous campaigns [38],
providing yet another indication that the sampling was
well conducted.
The age group included in the carriage study was the
same as the age group targeted for vaccination in 2010.
Since the entire country was vaccinated within a short
timeframe, the carriage study was not designed with a
non-vaccinated control group. However, since MenAfriVac
was not part of the Expanded Program of Immunization
and the study was performed two years after the national
mass vaccination campaign, 21.2% of the study participants
were considered non-vaccinated (17.6% reported to not be
vaccinated; 3.6% did not remember), and 70% of the 1-3-
year-olds were not vaccinated. The low vaccination co-
verage compared to previous studies [23,39] and the age
distribution of non-vaccinated was consistent with the
time delay between mass-vaccination in 2010 and the sur-
vey. Immigration might also contribute to explain the low
coverage but we did not collect such data. The reliability
of the participants’ responses to whether they had been
vaccinated with MenAfriVac is questionable, however, be-
cause the survey was conducted two years after vaccin-
ation and only 54.5% of those responding “yes” presented
a vaccination card. A relatively small number of 1- and 2-
year-olds were reported to have received MenAfriVac,
despite the fact that they were not eligible for vaccination
in 2010. It is possible that these children in fact had been
vaccinated in another country introducing the vaccine at a
later time point, but it is more likely a recall bias.
Carriage of NmA was still low two years after the intro-
duction of MenAfriVac, and together with the historically
low NmA disease incidence post-MenAfriVac vaccination,
our data support evidences of prolonged herd immunity
established after the mass vaccination campaign [23]. Des-
pite the fact that 70% of the 1-3-year olds were unvaccin-
ated, we did not find any NmA carrier in this age group.
In comparison, pre-vaccination NmA carriage prevalence
in the 1-3-year-olds was 0.30% [26]. Surprisingly, the sin-
gle NmA carriage isolate was ST-7 and not ST-2859, the
only genotype responsible for NmA disease in Burkina
Faso since 2004 [35], and also the only NmA genotype
found among carriers in the period 2008–2011 [26,27].
The child who carried this ST-7 strain had not travelled in
the period prior to sampling, but the household had re-
cently received visitors from the Ivory Coast, and colo-
nization of the child by a NmA ST-7 isolate might be a
result of transmission from one of the visitors.
The introduction of a monovalent vaccine could result
in capsule switch of the ST-2859 clone as a consequence
of uptake of genes coding for another capsule without
the loss of virulence, as has been described for other Nm
clones [40-43]. We have previously reported that we did
not observe any capsule switch up to 13 months after vac-
cination [24] and we show here that this observation was
still valid two years after vaccination.
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The most striking result in this carriage study was the
dominance of NmW ST-11 P1.5,2;F1-1, a clone that was
responsible for a large NmW outbreak in Burkina Faso
in 2000–2002. ST-11 was last detected among patients
in Burkina Faso in 2005 and 2006 [35,44] and was not
found among carriers in 2008–2010 [24,26], before it
reappeared during the epidemic season of 2011 [24]. It
has previously been suggested that the re-introduction
of ST-11 happened from Mali [24], and our results sup-
port this hypothesis since the western district of Dandé
had significantly higher NmW carriage prevalence when
compared to Bogodogo and Kaya. Dandé is close to Mali
and NmW caused districts on both sides of the Mali-
Burkina Faso border to reach the epidemic threshold in
2012 [36]. A reappearance of NmW ST-11 outbreaks ten
years after the 2002 outbreak [9,45] is consistent with
the cyclic waves of meningococcal epidemics [1,2]. Be-
fore MenAfriVac vaccination, the carriage prevalence of
NmA was low and the ST-11 clone did not circulate.
Thus, it is less likely that a vaccine-induced replacement
of NmA ST-2859 with NmW ST-11 could explain the
high proportion of NmW carriage and disease two years
after vaccination.
The second most frequent clone among carriers and
patients was NmX, ST-181 P1.5-1,10-1;F1-31. This same
clone caused many cases of meningitis during the epi-
demic season of 2010, before MenAfriVac introduction
[35]. NmX carriage was high in October-November 2010
and decreased throughout 2011 [23]. We show that car-
riage of NmX continued to decrease in 2012, but that
the district of Kaya still had the highest prevalence of
NmX. One of the culture-negative invasive NmX isolates
had the unusual PorA variant P1.7,16-46. A nested PCR
of the MLST loci attributed this isolate to the ST-181
complex, as the other NmX isolates.
Serogroup Y ST-4375 of the ST-23 complex was the
dominating carriage clone circulating in 2009, before
vaccine introduction [26], but its carriage prevalence
gradually declined in 2010–2011 [23] and only 0.6% of
the participants carried ST-4375 in 2012. The decline
in carriage of the ST-23 complex meningococci is pre-
sented in Figure 1. Compared to other virulent clones,
the ST-4375 clone is seldom associated with disease
and has been only sporadically identified in patients in
Burkina Faso in the past ten years, last in 2008 [35]. Al-
though various STs of the ST-23 complex have been
causing an increasing number of cases in the US and
Europe [46-48], only a few NmY cases of disease have
been reported in Burkina Faso, or in other countries of
the meningitis belt [35].
Since the start of these carriage campaigns, the domin-
ating serogroup has been Y (in 2009), X (in 2010–2011)
and W (in 2012) [23,26]. Carriage prevalence of each
of these serogroups varied significantly with age only
in the period when that serogroup was dominating.
In 2012 when serogroup W dominated, there was a
clear peak of carriage prevalence among the 5–9 year
old; in 2011 when serogroup X was dominating, max-
imum carriage was in 5–14 year old [23], and in 2009
when serogroup Y dominated, the peak was in the age
group 10–14 years [26].
We have also shown that the same genotypes were
found among carriers and patients and that increased
carriage of virulent clones was closely associated with in-
creased disease incidence. In Burkina Faso NmX ST-181
carriage prevalence increased during the epidemic sea-
son of 2009, especially in the eastern district of Kaya
[26] (Figure 1). In the following epidemic season (2010)
NmX was found to cause disease and towards the end of
2010, NmX ST-181 carriage was significantly higher in
all 3 carriage study sites, and particularly in Kaya [23,24]
(Figure 1). The same pattern was observed for NmW
ST-11, first seen among carriers in the western district
of Dandé in early 2011, then spreading throughout the
country [24]. The following epidemic season NmW ST-11
was the main disease-causing genotype and by the end of
2012, this clone dominated among carriage strains and
with the highest prevalence found in Dandé (Figure 1).
The introduction of virulent clones in an immunologic-
ally naive population seems to be one of the important
factors for meningococcal outbreaks [49], together with
the inherent properties of the various Nm serogroups
and clones, and contact patterns between individuals
within the society.
Conclusions
In this study we found that the carriage prevalence of
NmA was still very low in Burkina Faso two years after
MenAfriVac mass vaccination, with a single NmA carrier
identified among 4969 participants (0.02%). The isolate
was assigned to the ST-7, a genotype that has not circu-
lated in Burkina Faso since 2003. The most frequently
carried clone was NmW ST-11, a finding consistent with
the many cases of NmW meningitis in 2012 and the
high proportion of NmW ST-11 among the character-
ized invasive isolates.
The low NmA carriage prevalence in Burkina Faso two
years after MenAfriVac mass vaccination is consistent
with the historically low NmA disease incidence and con-
firms the vaccine’s long term ability to confer herd protec-
tion by preventing NmA colonization and transmission.
Until MenAfriVac is included in routine immunization
programs or is periodically administered through mass
vaccination campaigns [50], the unvaccinated population,
especially children who were too young to be vaccinated
in 2010, will benefit from low NmA transmission in their
entourage.
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